Navigating Healthcare Economics:
Optimizing Therapeutic Efficacy and Cost with Pharmacoeconomics
Abstract
Background: In today's healthcare landscape, escalating costs underscore the pressing need for pharmacoeconomic evaluations, particularly in low- and middle-income countries (LMICs) where medication expenses can dominate healthcare budgets. Pharmacoeconomics, a multidisciplinary field, scrutinizes the costs and benefits of healthcare interventions, offering vital insights for optimizing value within resource constraints. Methods: This article provides an overview of pharmacoeconomics, tracing its historical development, methodologies, and diverse applications in healthcare decision-making. Despite its significance, obstacles persist in the widespread adoption of pharmacoeconomic studies, including limited funding, expertise shortages, and data deficiencies. Addressing these challenges is paramount to harnessing the full potential of pharmacoeconomics in informing resource allocation and enhancing healthcare efficiency and sustainability worldwide. Results: As healthcare payers increasingly prioritize cost-effectiveness, the demand for pharmacoeconomic evaluations continues to grow, highlighting the urgent need for overcoming barriers to implementation. By embracing pharmacoeconomic principles, stakeholders can navigate complex healthcare landscapes, optimize patient outcomes, and promote equitable and efficient resource allocation. Ultimately, integrating pharmacoeconomics into healthcare decision-making processes holds promise for fostering a more resilient, effective, and patient-centered healthcare system for all.Adunlin G., Skiera J., Cupp C.S., Ali A.A. and Afeli S.A.Y., The State of Pharmacoeconomics Education in the Doctor of Pharmacy Curriculum amid the Changing Face of Pharmacy Practice., Healthcare (Basel)., 11(22), 2923 (2023)
Ahmad A., Patel I., Parimilakrishnan S., Mohanta G.P., Chung H. and Chang J., The role of pharmacoeconomics in current Indian healthcare system. J. Res. Pharm. Pract., 2(1), 3-9 (2013)
Alefan Q., Hamdouni E., Alhamad H., Mukattash T. and Rascati K., Barriers to implementing pharmacoeconomics: interview study., Expert. Rev. Pharmacoecon. Outcomes. Res., 21(1), 93-104 (2021)
Alzarea A.I., Khan Y.H., Alanazi AS, et al. Barriers and Facilitators of Pharmacoeconomic Studies: A Review of Evidence from the Middle Eastern Countries., Int. J. Environ. Res. Public. Health., 19(13), 7862 (2022)
Grega D. and Kolář J., Historical analysis of pharmacoeconomic terms, Scientometrics, 119(3), 1643–1654 (2019)
Kamaraj A., Agarwal N., Seah K.T.M. and Khan W., Understanding cost-utility analysis studies in the trauma and orthopaedic surgery literature. EFORT Open Rev., 6(5), 305-315 (2021)
Neumann P. J., Willke R. J., and Garrison L. P., A health economics approach to US Value Assessment Frameworks—Introduction: An Ispor Special Task Force Report [1], Value in Health, 21(2), 119–123 (2018)
Scaria S., Raju R., Joseph S., Mohan A. and Nair A.A. Pharmacoeconomics: Principles, Methods and Indian Scenario, Int. J. Pharm. Sci. Rev. Res., 34(1), 37-46 (2015)
Schmidt C., Matlala M., Godman B., Kurdi A. and Meyer J.C., Perceptions of and Preparedness for the Application of Pharmacoeconomics in Practice, among Final Year Bachelor of Pharmacy Students in South Africa: A National Cross-Sectional Study, Pharmacy (Basel)., 11(2), 54 (2023)
Tonin F.S., Aznar-Lou I., Pontinha V.M., Pontarolo Rl. and Fernandez-Llimos F. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions, Pharm. Pract (Granada)., 19(1), 2302 (2021)
Files | ||
Issue | Vol 11 No 01 (2025) | |
Section | Review Article(s) | |
Keywords | ||
Pharmacoeconomics Direct costs Indirect costs Intangible costs Cost-utility analysis (CUA) Cost-effectiveness analysis (CEA) Average cost-effectiveness ratio (ACER) Incremental cost-effectiveness ratio (ICER) Disability-adjusted life year Health-related quality of life (HRQOL) |
Rights and permissions | |
![]() |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |